Concentric Analgesics' new drug ca-008 for postoperative pain is recognized by FDA for breakthrough therapies

Today, Co
ncentric Bio
medicine(Inc.)(announced that it is thenew drug(recognized by the U.SFDA( a breakthrough therapythe CA-008 developed by the CA-
ncentric Analgesics is a non-opioiddrugof "first-in-class" (it can be quickly converted into a powerful TRPV1 agonist, capsaicin)After a single local injection, CA-008 can provide lasting pain relief by selectively desensitizing the pain's conduction nerve fibers, and does not produce numbness or weaknessinjections of CA-008 during surgery are expected to help patients eliminate the need for opioids during postoperative recoveryIt's worth noting that the drug was approved by the FDA in Decemberthe CA-008 was identified as a breakthrough therapy and was in a 1b placebo-controlled clinical trial (supported by data, in patients receiving a cystic excision nectomy) in this study, the highest dose of CA-008 reduced pain intensity by 63% compared to placebo, resulting in a statistically significant and clinically significant reduction in pain intensity CA-008 also showed statistically significant pain reduction at 48h, 72h, 96h, and 120h points in time important, opioid consumption in patients using CA-008 was reduced by nearly 50 percent compared to placebos In addition, studies have shown that CA-008 is safe and well tolerated at all doses